On Monday, Following U.S. Stocks were among the “Top Gainers”: Athersys, Inc. (NASDAQ:ATHX), Raytheon Company (NYSE:RTN), Francesca’s Holdings Corporation (NASDAQ:FRAN), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Athersys, Inc. (NASDAQ:ATHX), with shares inclined 5.67%, closed at $2.98.
Raytheon Company (NYSE:RTN), with shares jumped 2.89%, settled at $109.60.
Francesca’s Holdings Corporation (NASDAQ:FRAN), with shares climbed 5.37%, and closed at $16.10.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), surged 5.21%, and closed at $451.77, hitting new 52-week high of $452.36.
Latest NEWS regarding these Stocks are depicted underneath:
Athersys, Inc. (NASDAQ:ATHX)
Athersys, Inc. (ATHX), declared its financial results for the fourth quarter and year ended December 31, 2014.
Highlights of the fourth quarter of 2014 and recent events comprise:
- Accomplished patient enrollment of double blind, placebo-controlled Phase 2 study of MultiStem(R) cell therapy for ischemic stroke—initial results predictable in mid-April;
- Established partnership with Chugai Pharmaceuticals Co., Ltd. (“Chugai”) for development and commercialization of MultiStem cell therapy for ischemic stroke in Japan—license provides for more than $200 million in potential payments, counting $10 million up-front payment and $7 million tied to Phase 2 stroke study results;
- Prepared for launch of grant-supported Phase 2 AMI study at multiple sites, planned for 2ndquarter 2015;
- Received grant of up to [Pounds]2 million from Innovate UK to support Phase 2a study evaluating administration of MultiStem therapy to ARDS patients in United Kingdom;
- Granted Fast Track Designation by FDA for prophylaxis therapy for graft-as compared to-host disease following hematopoietic cell transplantation;
- Recorded proceeds of $0.2 million and net loss of $6.6 million for quarter ended December 31, 2014; and proceeds of $1.6 million and net loss of $22.1 million for year ended December 31, 2014; and
- Ended year with $26.1 million in cash and cash equivalents.
Athersys is an international biotechnology corporation engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Corporation is developing its MultiStem cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product.
Raytheon Company (NYSE:RTN)
Raytheon Company (RTN), declared a $10 million pledge to support initiatives aimed at empowering service members and their families through education opportunities. The new five-year commitment will support science, technology, engineering and math education and mentorship programs in partnership with Boys & Girls Clubs of America and Student Veterans of America.
Raytheon’s Chairman and CEO Thomas A. Kennedy said the new initiative builds upon the corporation’s commitment to support the men, women and families of the armed services.
Boys & Girls Clubs of America are a constant presence in the life of a military child, with a BGCA-associated youth center on nearly every U.S. military installation and in communities with a strong military presence. The organization partners with every branch of the U.S. military serving nearly half a million school-age military youth.
Student Veterans of America chapters are run by and for student veterans. The organization is the world’s largest network of student veteran groups with more than 1,100 chapters in all 50 states and four countries, providing a peer support network that is critical to a veteran’s successful transition to academic life. SVA’s national initiatives and campus-based model focuses solely on enabling veterans to graduate with market-valued degrees.
Raytheon Corporation develops integrated products, services, and solutions in the areas of sensing; effects; command, control, communications, and intelligence; mission support; and cyber and information security worldwide.
Francesca’s Holdings Corporation (NASDAQ:FRAN)
Francesca’s Holdings Corporation (FRAN), declared plans to report fourth quarter and fiscal year 2014 financial results on Wednesday, March 25, 2015, before the market opens. The Corporation also plans to hold a conference call to talk about its financial results the same day at 8:30 a.m. ET.
In addition, a replay of the call will be accessible shortly after the conclusion of the call and will remain accessible until April 1, 2015. To access the telephone replay, listeners should dial 1-877-870-5176. The access code for the replay is 2008821. A replay of the webcast will also be accessible within two hours of the conclusion of the call and will remain on the website for ninety days.
Francesca’s Holdings, is a growing specialty retailer with retail locations designed and merchandised to feel like independently owned, upscale boutiques providing customers a fun and differentiated shopping experience. The merchandise assortment is a diverse and balanced mix of apparel, jewelry, accessories and gifts. Recently francesca’s(R) operates 568 boutiques in 47 states and the District of Columbia and also serves its customers through francescas.com.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (REGN), and Sanofi, declared that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or “bad” cholesterol) by an additional 62 percent at week 24 when contrast to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical corporation, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
